Compass Therapeutics Inc (NASDAQ:CMPX) has a beta value of 1.19 and has seen 14.59 million shares traded in the recent trading session. The company, currently valued at $275.88M, closed the recent trade at $2.00 per share which meant it gained $0.1 on the day or 5.00% during that session. The CMPX stock price is -104.0% off its 52-week high price of $4.08 and 62.0% above the 52-week low of $0.76. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.92 million shares traded. The 3-month trading volume is 1.58 million shares.
The consensus among analysts is that Compass Therapeutics Inc (CMPX) is Buy stock at the moment, with a recommendation rating of 1.30. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.11.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Sporting 5.00% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CMPX stock price touched $2.00 or saw a rise of 7.83%. Year-to-date, Compass Therapeutics Inc shares have moved 37.59%, while the 5-day performance has seen it change -7.85%. Over the past 30 days, the shares of Compass Therapeutics Inc (NASDAQ:CMPX) have changed -26.92%. Short interest in the company has seen 4.61 million shares shorted with days to cover at 5.43.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 60.0% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -150.0% off the targeted high while a plunge would see the stock gain -150.0% from the levels at last check today.
Compass Therapeutics Inc (CMPX) estimates and forecasts
The company’s shares have gained 6.12% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 44.71%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -104.70% over the past 5 years. Earnings growth for 2025 is a modest -25.56% while over the next 5 years, the company’s earnings are expected to increase by 33.35%.
CMPX Dividends
Compass Therapeutics Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
Insiders own 18.08% of the company shares, while shares held by institutions stand at 70.96% with a share float percentage of 86.62%. Investors are also buoyed by the number of investors in a company, with Compass Therapeutics Inc having a total of 120.0 institutions that hold shares in the company. The top two institutional holders are ORBIMED ADVISORS LLC with over 22.36 million shares worth more than $22.36 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 16.2534% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 11.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.13 million and represent 8.0893% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 5.01% shares in the company for having 2.61 shares of worth $5.56 million while later fund manager owns 2.59 shares of worth $5.52 million as of Feb 28, 2025, which makes it owner of about 4.97% of company’s outstanding stock.
